Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.


home / news releases / IXHL - Incannex Company Presentation - Results from Phase 1 Clinical Trial to Assess Proprietary IHL-675A

IXHL - Incannex Company Presentation - Results from Phase 1 Clinical Trial to Assess Proprietary IHL-675A

Incannex Healthcare Limited

MELBOURNE, Australia, May 03, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Ltd (Nasdaq: IXHL) (ASX: IHL) (‘Incannex’ or ‘the Company’) is pleased to announce a company presentation containing data and analysis of the results from the Phase 1 clinical trial undertaken to assess safety and pharmacokinetics of IHL-675A as an anti-inflammatory drug candidate.

A Media Snippet accompanying this announcement is available by clicking on the image or link below:

Incannex Contact Information:

Incannex Healthcare Limited
Mr Joel Latham
Managing Director and Chief Executive Officer
+61 409 840 786
joel@incannex.com.au

Investor Relations Contact – United States
Alyssa Factor
Edison Group
+1 (860) 573 9637
afactor@edisongroup.com


Stock Information
Company Name: Incannex Healthcare Limited
Stock Symbol: IXHL
Market: NASDAQ
Website: incannex.com.au
Menu
IXHL IXHL Quote IXHL Short IXHL News IXHL Articles IXHL Message Board
Get IXHL Alerts

News, Short Squeeze, Breakout and More Instantly...